头颈癌的放射免疫治疗:机制与临床前景
本文综述了头颈鳞状细胞癌(HNSCC)中放疗与免疫检查点抑制剂联合的临床前与临床证据,探讨放疗如何重塑肿瘤微环境以增强抗肿瘤免疫应答,并提出优化放射免疫治疗、设计未来试验及解读免疫治疗数据的机制框架。
要点
- 免疫检查点抑制剂在多数HNSCC患者中获益有限,联合治疗策略是研究重点。
- 放疗除直接杀伤肿瘤外,可改变肿瘤微环境免疫细胞组成与丰度。
- 放疗联合免疫治疗已在包括HNSCC的多种肿瘤中显示可诱导强效抗肿瘤免疫应答。
核心结论
- 放疗可通过重塑肿瘤微环境增强HNSCC对免疫检查点抑制剂的应答,机制洞察有助于最大化放射免疫治疗的应用并指导未来试验设计。
研究设计与样本
- 本系列论文基于已发表的临床与临床前数据,综述放疗在HNSCC免疫治疗背景下的治疗潜力。
主要发现
- 临床前证据表明放疗可帮助创建并维持免疫允许性环境,影响肿瘤浸润免疫细胞的丰度与组成。
- 放疗联合免疫治疗在包括HNSCC的多种癌症中可诱导强效抗肿瘤免疫应答。
临床怎么用
- 在HNSCC免疫治疗中应充分考虑放疗对肿瘤微环境的调节作用,以优化联合治疗策略。
- 机制性认识可为疾病控制中放射免疫治疗的最大化应用、未来试验设计及新兴免疫治疗数据解读提供基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Evidence to date shows that immune checkpoint inhibitors have little benefit in most patients with head and neck squamous cell carcinoma (HNSCC). Intense interest is focused on identifying and developing rational combinations of immune checkpoint inhibitors and different therapeutic interventions to enhance response rates and overcome immune checkpoint inhibitor resistance. Combining radiotherapy, a primary HNSCC treatment modality, with immunotherapy has been shown to induce potent antitumour immune responses in many cancers including HNSCC. In addition to its direct cytotoxic effect on the cancer cell, radiotherapy can shape the tumour microenvironment to affect the abundance and composition of tumour-infiltrating immune cells and therefore change responses to immune checkpoint inhibitor therapy. In this Series paper, we examine how radiotherapy can be used to its maximum therapeutic potential in the setting of immunotherapy treatment for HNSCC by focusing on published clinical and preclinical data. We rely on preclinical evidence for this disease to discuss how radiotherapy can help create and maintain an immunologically permissive environment. Our hope is that such mechanistic insights will provide a foundation for maximising the use of radioimmunotherapy in disease control, designing future trials, interpreting emerging immunotherapy data, and accelerating discovery within radioimmunotherapy interventions for HNSCC.
引用
- Karam SD, Raben D. Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol. 2019. PMID: 31364593. doi:10.1016/S1470-2045(19)30306-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。